GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Wanbury Ltd

Wanbury Ltd Q2 & H1 FY27 Investor Presentation Released

RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 18 Nov 2026, 12:40 PM IST  ·  BSE ID: eb7b0d5a-ee91-46af-a6a2-801b7b9d97bb
View Original BSE Filing (PDF)
💡
In Simple Terms
The company published a presentation for investors detailing its financial results and business strategy for the recent quarter.
🤖 AI Summary
  • Wanbury Ltd submitted an Investor Presentation for Q2 and Half Year ended 30 September 2026.
  • The presentation details a successful global turnaround and growth momentum for the company.
  • Highlights include global market leadership in Metformin & Sertraline APIs and new growth drivers.
  • The company reports operational and financial turnaround over the last three years, including debt reduction.
  • Wanbury operates with 88% of its FY26 revenue from API business and 12% from Formulations business.
🏢 How This Affects the Company
📈
Business Impact
The presentation reiterates Wanbury's focus on building new growth drivers in its API business and rebuilding its legacy brand formulations business in India. This confirms the ongoing strategy of expanding product launches and focusing on regulatory markets.
💰
Financial Impact
The company highlights a ~75% debt reduction from its peak of ~700 Crores and a reduction in borrowing cost from 22.5% to 12.5% effective March 1, 2025. This indicates an improved capital structure and reduced interest expenses.
⚙️
Operational Impact
Capacity ramp-up in key API products like Metformin (25% increase) and Sertraline (20% increase) through de-bottlenecking projects suggests increased production capability. This supports the strategy of operational scale-up and efficient procurement.
⚠️
Risk Impact
The successful business turnaround and de-risked balance sheet, including debt refinancing, indicate a reduction in financial risk. The focus on established global regulatory approvals also mitigates market entry risks in developed markets.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this disclosure.
👤
Who Is Affected
Shareholders receive a comprehensive overview of the company's performance, strategic direction, and financial health for Q2 & H1 FY27, confirming previously released results.
🔍
Management Signal
The presentation signals management's focus on transparent communication, strategic debt reduction, operational efficiency, and a clear path for future business growth.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — observe if debt reduction and operational improvements continue to impact profitability.
Updates on new API product commercialization — track actual launches and market reception.
Status of Formulations business rebuilding efforts — monitor revenue contribution and profitability.
LOW RISK This filing is a presentation of information already largely disclosed, carrying no new immediate risks.
💡 Investor Takeaway
Wanbury Ltd's investor presentation for Q2 & H1 FY27 confirms a successful business turnaround including ~75% debt reduction from peak ~700 Crores and reduced borrowing costs to 12.5%. Operational capacity increased for Metformin and Sertraline, supporting growth momentum.
⚖️ Strengths & Concerns

✅ Positives

  • ~75% debt reduction from peak obligation of ~700 Crores, reducing financial leverage and improving balance sheet health.
  • Reduction in borrowing cost from 22.5% to 12.5% effective March 1, 2025, lowering financing expenses.

⚠️ Concerns

  • The presentation confirms previously reported Q2 FY27 results but does not contain new financial data for the period.
  • Specific numerical targets for future growth drivers or new product commercialization are not detailed in the summary sections.
📅 Company Track Record
Wanbury Ltd reported Q2 FY27 revenue up 14.28% to Rs. 18,290.97 Lakhs, with PAT down 21.72% to Rs. 1,188.23 Lakhs, as per previous filings on November 4 and 6, 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What period does Wanbury Ltd's investor presentation cover?
The investor presentation covers the second quarter and half year ended 30th September 2026, which corresponds to Q2 & H1 FY27.
What financial improvements did Wanbury Ltd highlight in the presentation?
Wanbury Ltd highlighted a ~75% reduction in debt from a peak obligation of ~700 Crores and a reduction in borrowing cost from 22.5% to 12.5% effective March 1, 2025.
What operational changes were noted for Wanbury Ltd's API business?
Operational changes include a 25% increase in Metformin capacity and a 20% increase in Sertraline capacity in the last three years through de-bottlenecking.
What were Wanbury Ltd's API and Formulations revenue contributions in FY26?
In FY26, Wanbury Ltd's API business contributed 88% of the revenue, totaling ₹574 Crore, while the Formulations business contributed 12%, totaling ₹76 Crore.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses free when you sign up

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.

Live IPO, GMP and market updates on Telegram

IPO open and close dates, grey market premium moves, subscription figures, allotment and listing days, and the market updates worth knowing about, posted on the channel as they happen.

Join the channel